亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

南京克萊森醫(yī)藥化工有限公司  

普瑞巴林中間體，替卡格雷中間體，達比加群酯中間體，羅匹尼羅中間體，利克飛龍中間體，阿扎那韋中間體，拉帕替尼中間體，埃羅替尼中間體，伐侖克林中間體，地瑞那韋中間體，阿替美唑中間體，依替米貝中間體
搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人：徐罡
  • 電話：025-83172646
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產(chǎn)品 > 普瑞巴林中間體185815-61-6
普瑞巴林中間體185815-61-6
單價 面議對比
詢價 暫無
發(fā)貨 江蘇南京市付款后3天內(nèi)
品牌 (R)-3-(羰基甲基)-5-甲基己酸
型號 185815-61-6
規(guī)格 185815-61-6
過期 長期有效
更新 2012-05-31 12:07
 
詳細信息

Cas: 185815-61-6(R)-3-(羰基甲基)-5-甲基己酸       
Name of product：(R)-3-(CARBAMOYLMETHYL)-5-METHYLHEXANOIC ACID
Formula: C9H17NO3
Molecular weight: 187.23618
Molecular structure:
Remark：Pregabalin intermediate
©2025 南京克萊森醫(yī)藥化工有限公司 版權(quán)所有   技術(shù)支持：化工網(wǎng)   訪問量:9969  
 
主站蜘蛛池模板： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |